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Received 26 November 2004; received in revised form 2 March 2005; accepted 2 March 2005AbstractThe minimal inhibitory concentrations (MICs) of tylosin were determined to 67 strains of Paenibacillus larvae subsp. larvae,
the causal agent of American Foulbrood (AFB) disease, from different geographical origins. MIC values obtained ranged from
0.0078 to 0.5 mg/ml. These very low values imply that no resistance to tylosin was found in any isolate of the Foulbrood
pathogen.
The measurement of diseased larvae with AFB-clinical symptoms in three different field studies demonstrated that tylosin
treatment could be effective in vivo. No negative effects in colonies were noted at any dosage rates or forms of application. These
studies demonstrate that tylosin, as tartrate, can be used to treat AFB in honeybee colonies.
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American Foulbrood (AFB) disease caused by the
spore-forming bacterium Paenibacillus larvae subsp.
larvae (P.l. larvae) (Heyndrickx et al., 1996) (formerly* Corresponding author. Tel.: +54 221 4271341;
fax: +54 221 4252346.
E-mail address: amalippi@netverk.com.ar (A.M. Alippi).
0378-1135/$ – see front matter # 2005 Elsevier B.V. All rights reserved
doi:10.1016/j.vetmic.2005.03.008Bacillus larvae) is a cosmopolitan disease of bacterial
origin affecting the larval and pupal stages of
honeybees (Apis mellifera L.) (White, 1920; Shima-
nuki, 1990). Diseased individuals turn brown, then
black, and the resultant mass becoming a hard scale of
material deposited on the side of the cell. AFB is one
of the few bee diseases capable of killing a colony,
and has unique problems for prevention and control
because the spores can remain viable for long periods.
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eson and Reid, 1992). The disease is highly contagious
and if undetected can kill a colony and spread to others
within the same apiary or to another apiary nearby by
robbing and exchanging of brood combs, the main
sources of contamination.
In areas where disease incidence is high, antibiotic
treatments appear as an alternative to the burning of
diseased bee colonies. Currently, the only antibiotic
approved for prevention and control of AFB is
oxytetracycline, however, there is evidence of oxyte-
tracycline-resistant isolates of P.l. larvae in certain
areas of the USA, Canada and Argentina (Alippi, 2000;
Colter, 2000; Evans, 2003; Miyagi et al., 2000).
The antibiotic tylosin, as tartrate, has been shown to
be an alternative to oxytetracycline for the control of
AFB in several studies (Alippi et al., 1999; Elzen et al.,
2002a,b; Hitchcock et al., 1970; Moffett et al., 1970;
Peng et al., 1996). Tylosin is virtually non-toxic to
adult honeybees (Alippi et al., 1999) and less toxic
than oxytetracycline to honeybee larvae (Peng et al.,
1992, 1996).
The purposes of the present work were to evaluate
the susceptibility of 67 strains of P.l. larvae from
diverse geographical areas to tylosin by determining
their minimal inhibitory concentrations (MIC), since
the information about their efficacy in vitro is quite
limited (Alippi, 1994; Kochanski et al., 2001;
Okayama et al., 1996) and to determine the response
of colonies with clinical signs of AFB to tylosin at
different doses and forms of application in order to
determine the most effective dose for disease control
and lack of recurrence of the disease.2. Materials and methods
2.1. Bacterial strains
The 67 P.l. larvae strains from diverse geographical
origins used in this study are listed in Table 1. For the
isolation of P.l. larvae strains from larvae affected by
AFB and from honey samples, previously described
techniques were employed (Alippi, 1995; Alippi and
Aguilar, 1998; Alippi et al., 2004). In addition,
reference strains from culture collections were
included, and also strains of Pseudomonas aeruginosa,
Escherichia coli and Staphylococcus aureus used asreference standards for quality control ranges of MICs
were provided by Instituto Malbra´n Collection,
Instituto Malbra´n, Buenos Aires, Argentina (Table 1).
2.2. Determination of minimal inhibitory
concentrations of tylosin
As there is no NCCLS recommendation for the
determination of MICs of P.l. larvae, a method
developed for this species was used based on the
NCCLS standard for Bacteria isolated from animals
(NCCLS, 1999). Minimal inhibitory concentrations of
tylosin tartrate (Sigma1) were determined by the agar
dilution method using MYPGP (Dingman and Stahly,
1983) as basal medium because P.l. larvae is not able to
growth on Muller–Hinton agar. Tylosin concentrations
tested were made using a stock solution of 5000 mg/ml
in distilled water and sterilized using a syringe-driven
filter unit with a 0.22 mm pore size. Appropriate
dilutions were made in sterile distilled water and stored
at 20 8C until used. The medium was maintained at
45 8C until the antibiotic solutions were incorporated
and 25 ml of culture medium were poured onto each
Petri plate of 90 mm in diameter. Increasing concen-
trations of tylosin tested were: 0.0039, 0.0078, 0.015,
0.03125, 0.0625, 0.125, 0.5, 1, 2, 4, 8, 16 and 32 mg/ml
of medium. For the controls, MYPGP agar without
antibiotic was employed.
Vegetative cells of each P.l. larvae strain grown on
MYPGP agar for 48 h of incubation at 37 8C were
suspended in sterile distilled water and adjusted to
approximately 2.87  108 cells/ml (A620 nm = 0.388,
equivalent to a Mc Farland standard of 1). The different
bacterial strains were layered by using an automatic
micropipette to place drops of 10 ml each over the
surface of the solidified culture medium containing
each antibiotic concentration. Ten replications were
tested for each strain. The inoculated plates were
examined for growth after 48 h of incubation at 37 8C.
The lowest concentration of antibiotic preventing
growth was defined as the MIC (complete inhibition
of bacterial growth on the test plates, disregarding a
single colony of faint haze caused by inoculum).
In the case of P. aeruginosa, E. coli and S. aureus
used as reference standards, the technique outlined by
the NCCLS for each species (NCCLS, 1999) was
followed, with the only difference that MYPGP agar
was used as basal medium.
A.M. Alippi et al. / Veterinary Microbiology 109 (2005) 47–55 49
Table 1
Minimal inhibitory concentration values (MICs) (mg/ml) for selected isolates and designation and origin of the bacterial strains used in this study
Strain Other designation Geographical origin Source Year MIC
Paenibacillus larvae subsp. larvae
PL3 Concordia, Entre Rı´os, Argentinaa Diseased larvae 1992 0.0625
PL7 Pigu¨e, Buenos Aires, Argentinaa Diseased larvae 1992 0.125
PL14 San Martı´n, La Pampa, Argentinaa Diseased larvae 1995 0.0625
PL15 La Plata, Buenos Aires, Argentinaa Diseased larvae 1995 0.0625
PL21 New Zealandb Diseased larvae 1995 0.03125
PL25 New Zealandb Diseased larvae 1995 0.125
PL30 New Zealandb Diseased larvae 1995 0.03125
PL32 Arroyo Alegre, Co´rdoba, Argentinaa Diseased larvae 1995 0.03125
PL33 Cha´scomus, Buenos Aires, Argentinaa Diseased larvae 1995 0.5
PL34 Valle Medio, Rio Negro, Argentinaa Diseased larvae 1995 0.0625
PL35 Chimpay, Rio Negro, Argentinaa Diseased larvae 1995 0.125
PL41 Lecce, Italyc Diseased larvae 1991 0.125
PL42 Modena, Italyc Diseased larvae 1992 0.015
PL44 Padova, Italyc Diseased larvae 1995 0.25
PL45 Vanchuse, Franced Diseased larvae 1995 0.03125
PL49 Var, Franced Diseased larvae 1995 0.0625
PL51 Lincoln, Buenos Aires, Argentinaa Diseased larvae 1995 0.5
PL57 Uppsala, Swedene Diseased larvae 1995 0.125
PL58 Uppsala, Swedene Diseased larvae 1995 0.03125
PL59 Uppsala, Swedene Diseased larvae 1995 0.015
PL64 Ranchos, Buenos Aires, Argentinaa Honey 1995 0.5
PL71 Grye, Polandf Received as a culture 1996 0.25
PL73 Skierne, Polandf Received as a culture 1996 0.125
PL74 CCM 4483 Czech Republicg Culture – 0.03125
PL76 CCM 4485 Czech Republicg Culture – 0.125
PL78 Argentinaa Honey 1996 0.125
PL81 Dufaur, Buenos Aires, Argentinaa Diseased larvae 1996 0.0625
PL85 New York, USAh Diseased larvae 1996 0.0625
PL89 Holzkirchen, Germanyi Diseased larvae 1994 0.0625
PL90 Holzkirchen, Germanyi Diseased larvae 1994 0.125
PL91 Holzkirchen, Germanyi Diseased larvae 1994 0.03125
PL95 Devon, UKj Received as a culture 1997 0.25
PL96 Leicester, UKj Received as a culture 1997 0.125
PL97 Kent, UKj Received as a culture 1997 0.0625
PL99 Argentinaa Commercial honey 1997 0.125
PL100 Tuniciaa Honey 1997 0.125
PL101 ATCC 9454 USAk Received as a culture – 0.125
PL102 Argentinaa Commercial honey 1998 0.5
PL103 NRRL B 3555 USAl Received as a culture – 0.125
PL104 ATCC 2574 USAk Received as a culture – 0.03125
PL155 Magdalena, Buenos Aires, Argentinaa Honey 1999 0.0625
PL202 Italya Commercial honey 1999 0.5
PL206 Gral. Pinto, Buenos Aires, Argentinaa Honey 1999 0.25
PL212 Toronto, Canadaa Commercial honey 1999 0.125
PL213 Toronto, Canadaa Commercial honey 1999 0.25
PL214 Toronto, Canadaa Commercial honey 1999 0.125
PL231 Francea Commercial honey 1999 0.0625
PL238 Francea Commercial honey 1999 0.25
PL252 Spainm Received as a culture 2000 0.125
PL255 Spainm Received as a culture 2000 0.0625
PL284 Nueva Palmira, Uruguayn Received as a culture 2000 0.03125
PL286 Paysandu´, Uruguayn Received as a culture 2000 0.03125
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Table 1 (Continued )
Strain Other designation Geographical origin Source Year MIC
PL287 Nueva Palmira, Uruguayn Received as a culture 2000 0.03125
PL289 P41 Japano Received as a culture 2000 0.03125
PL290 P55 Japano Received as a culture 2000 0.03125
PL295 USAa Commercial honey 2000 0.015
PL304 West Flanders, Belgiump Received as a culture 2001 0.125
PL305 Brabant, Belgiump Received as a culture 2001 0.03125
PL316 Mar Chiquita, Buenos Aires, Argentinaa Honey 2001 0.125
PL318 Chilem Received as a culture 2001 0.5
PL319 Chilem Received as a culture 2001 0.125
PL339 Chilem Received as a culture 2001 0.125
PL368 Buzios, Brazila Commercial honey 2001 0.03125
PL373 Boston, USAa Commercial honey 2001 0.015
PL374 Boston, USAa Commercial honey 2001 0.015
PL380 Brandsen, Buenos Aires, Argentinaa Honey 2001 0.0039
PL381 La Plata, Buenos Aires, Argentinaa Honey 2001 0.03125
Pseudomonas aeruginosaq ATCC 27853 Received as a culture – >32
Staphylococcus aureusq ATCC 29213 Received as a culture – 2
Escherichia coliq ATCC 29922 Received as a culture – >32
a Source of strains: A.M. Alippi, Centro de Investigaciones de Fitopatologı´a, Facultad de Ciencias Agrarias y Forestales, UNLP, La Plata,
Argentina.
b M.R. Goodwin, Apicultural Research Unit, Ruakura Research Center, Hamilton, New Zealand.
c Dr. E. Carpana, Istituto Nazionale de Apicoltura, Bologna, Italy.
d Dr. Marc Colin, Station de Phytopharmacie, INRA Avignon, Montfavet Cedex, France.
e I. Fries, Bee Division, Swedish University of Agricultural Sciences, Uppsala, Sweden.
f M. Jelinski, Instytut Weterynarii, Swarzdez, Poland.
g CCM, Czech Collection of Microorganisms, Brno, Czech Republic; CCT, Colec¸ao de Culturas Tropical, Fundac¸ao Andre´ Tosello, Campinas,
SP, Brazil.
h Dr. Marta Gilliam, Carl Hayden Honey Bee Research Center, USDA-ARS, Tucson, AZ, USA.
i U. Rdest, Biozentrum der Universita¨t Wu¨rzburg, Lehrstuhl Mikrobiologie, Germany.
j B. Dancer, School of Pure and Applied Biology, University of Wales, Cardiff, UK.
k ATCC, American Type Culture Collection, Rockville, MD, USA.
l NRRL, Northern Utilization Research and Development Division, Peoria, IL, USA.
m P. Avalos, Laboratorio y Estacio´n Cuarentenaria Lo Aguirre, SAG, Chile.
n C. Piccini, Lab. Microbiologı´a, Instituto de Investigaciones Biolo´gicas Clemente Estable, Montevideo, Uruguay.
o A. Kataoka, Research Institute for Animal Science in Biochemistry and Toxicology, Kanawaga, Japan.
p W. Dobbelaere, Veterinary and Agrochemical Research Centre, Brussels, Belgium.
q Instituto Malbra´n, Buenos Aires, Argentina.2.3. Field experiments
The efficiency of tylosin tartrate for the control of
AFB on diseased bee colonies was evaluated on three
field experiments conducted at the Faculty of
Agricultural Science Experimental Field, UNLP, La
Plata 35 8S latitude, 57 8W longitude. In all experi-
ments, colonies of honeybees derived from Apis
mellifera ligustica L. were used. Queens were marked
and their wings were clipped to avoid swarming.
Colonies were distributed in a completely randomized
design. The experimental procedures for inoculation
were conducted as described by Alippi et al. (1999).The amount of healthy brood, adult bees and larvae
with AFB-clinical symptoms were measured in the
same way in all of the experiments. Healthy brood
cells (larvae and pupae) were quantified according to
the following scale: grade 0, absence of brood cells;
grade 0.5, between 1 and 499 brood cells; grade 1,
between 500 and 3499 brood cells; grade 2, between
4000 and 7999 brood cells; grade 3, between 8000 and
11,499 brood cells; grade 4, between 12,000 and
15,999 brood cells and grade 5, between 16,000 and
more than 16,000. The number of adult bees were
quantified in a similar manner, with a minimum of
grade 0 and a maximum grade 5, being grade 0,
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16,000 bees per colony. Measurement of clinical signs
of AFB were estimated according to a seven levels
scale, where level 0 is non-detectable AFB symptoms;
level 1, between 1 and 10 larvae with clinical signs of
AFB; level 2, between 11 and 30 larvae with clinical
signs of AFB; level 3, between 31 and 99 larvae with
clinical signs of AFB; level 4, more than 100 larvae
with clinical signs of AFB; level 5, Queen supersedure
due to AFB and level 6, colony death, respectively.
The first experiment started in March and ended in
October 2000. The 10 colonies used were from packs
graded 4 for bees, 3 for brood and 0 for AFB-infection.
Two treatments with five repetitions each were
applied: five colonies were treated with 1.5 g of
tylosin tartrate (Tylan Esanco1) and five colonies
were used as AFB-inoculated controls. The total dose
(1.5 g per colony) was divided in six parts preparing
70 g candies (55 g powdered sugar + 15 g 55% sugar
syrup + 0.25 g active ingredient (a.i. of tylosin
tartrate); cherry jelly was used as an attractant to
ensure consumption. For controls a mixture of
powdered sugar, sugar syrup and cherry jelly was
used. The first candy was supplied as preventive 15
days before the inoculations of colonies with AFB-
contaminated combs containing 20  5 scales (Alippi
et al., 1999). Inoculated colonies were evaluated once
a month starting 30 days after inoculation. Each candy
was replaced with a new one every 2 weeks. At the end
of the experiment disease recurrence was also
evaluated.
The second experiment was carried out between
April and August 2001. The 10 colonies used were
from packs graded 4 for bees, 3 for brood and 0 for
AFB disease signs. Inoculations and evaluation of
colonies were managed like those in the first
experiment, but with modifications in doses and form
of administration of the antibiotic. Two treatments
with five repetitions each were applied: five colonies
were treated with 0.750 g tylosin tartrate in a 70 g
candy 15 days before inoculation and five colonies
used as AFB-inoculated controls were supplied with a
70 g candy. Four monthly inspections were made
starting 30 days after infection.
The third experiment took place between May and
October 2002. Twelve colonies were used and were
graded 4 for bees, 3 for brood and 0 for AFB-infection.
The differences with the former experiment were: thetreatments were applied by means of monthly supplied
syrup. Six colonies were treated with 0.750 g tylosin
tartrate and six colonies were used as AFB-inoculated
controls (50% sacarose syrup). The total dose of
tylosin for the first group was provided at the first
application with 750 cc of syrup 30 days after
infection. Four monthly applications of 50% syrup
without antibiotic were made afterwards. Controls
were supplied in five monthly applications consisting
of 750 cc 50% sacarose syrup. Taste was improved by
adding 0.5 ml raspberry essence to each jar.
2.4. Statistical analysis
Wilcoxon two-sample test was used for analyzed
significant differences ( p < 0.05) between colonies
treated with tylosin and untreated controls in each
experiment as described by Spivak and Reuter (2001).
Mantel Haenszel Chi-square test and also Fisher exact
test (two tails), specially suited for small samples,
were run in order to estimate the infection among
treatments ( p < 0.05) in all three experiments. In the
same way, the Fisher exact test was used to estimate
significant differences in the number of brood cells
and that of adult bees between tylosin treatments and
AFB-inoculated controls. Results from all three
experiments were combined for that purpose (Spivak
and Reuter, 2001).3. Results and discussion
3.1. Minimum inhibitory concentrations of tylosin
MYPGP probed adequate for growth and inter-
pretation of MIC values of P.l. larvae and also results
for P. aeruginosa, E. coli and S. aureus are within the
acceptable limits for quality control strains (NCCLS,
1999). All P.l. larvae strains were highly susceptible to
tylosin with MIC values ranging from 0.0078 to
0.5 mg/ml depending upon the tested strain (Fig. 1).
Results are summarized in Table 1. These values
indicate that very low concentrations of tylosin are
required to inhibit the growth of P.l. larvae. The
appearance of oxytetracycline-resistant P.l. larvae
strains in many countries has given a high priority to
the search of alternatives being tylosin highly effective
for the control of the Foulbrood pathogen in vitro
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Fig. 1. Frequency of MICs for tylosin between the Paenibacillus larvae subsp. larvae isolates tested.when testing 67 strains from different geographical
origins. These results are in accordance with previous
studies on strains from Japan, where MIC values were
between 0.025 and 0.1 mg/ml (Okayama et al., 1996).
The National Committee for Clinical Laboratory
Standards do not provide a standard method for
determining MIC values for P.l. larvae (NCCLS,
1999), nor have breakpoints for antibiotic resistance
been established. The values of MIC obtained using
MYPGP agar for reference strain of P. aeruginosa
ATCC 27853 MIC > 32, S. aureus ATCC 29213
MIC = 2 and E. coli ATCC 29922 MIC > 32 are
within the acceptable limits for quality control strains,
being >32, between 0.5 and 4 mg/ml and >32,
respectively. Isolates could be considered as suscep-
tible when their MICs were8, intermediate for MICs
of 16 and resistant for MICs  32, as suggested for
tylmicosin (NCCLS, 1999) or resistant when their
MICs were 4 as considered for many antibiotics
(Gales et al., 2001). Based upon the results of the
present study, there are not any P.l. larvae resistant or
intermediate strains for tylosin. Further studies that
include resistant and/or intermediate P.l. larvae strains
are needed to corroborate this hypothesis, but until
present there is not tylosin resistance reported for this
species.
3.2. Field experiments
In the first field experiment, three out of five AFB-
inoculated control colonies showed symptoms 60 days
after inoculation, and 150 days after inoculation, allcolonies showed clinical signs ranging from level 1 to
level 6. On the other hand, the colonies treated with
tylosin showed no symptoms at all. The results from
the first field experiment showed that the disease was
controlled in all of the treated colonies and no
recurrence of the disease was observed after the end of
the experiment by using six candies of 250 mg tylosin
(Table 2 and Fig. 2).
During the second field experiment two colonies
treated with tylosin showed symptoms 90 days after
inoculation (level 1). One colony recovered 120 days
after inoculation (level 0) and the other remained
with less than three larvae affected (level 1) (Table 3).
One of the AFB-inoculated controls showed symp-
toms after 30 days. After 90 days, all AFB-inoculated
controls showed clinical signs of the disease and
the infection increased throughout the end of the
experiment (ranging from level 1 to level 6) (Table 3).
The results from the second field experiment
showed that the disease was controlled in 80% of
the treated colonies and no recurrence of the disease
was observed after the end of the experiment by
using one candy of 750 mg of tylosin (Table 3 and
Fig. 2).
In the third field experiment, after 90 and 120 days
of the infection, in the tylosin treatments, no AFB
diseased larvae were found, and after 150 days one
colony exhibited two larvae with clinical symptoms of
AFB (level 1). The AFB-inoculated controls showed
clinical signs in three of them 60 days after infection
(level 1). Two of them died after 90 and 120 days,
respectively (level 6) (Table 4 and Fig. 2).
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Table 2
Clinical symptoms of AFB and amount of healthy brood and adult bees per colony and inspection date during the first field experiment starting in
March 29, 2000
Treatment Colony
number
May 29 July 11 August 11 September 11 October 17
Brood Bees AFB Brood Bees AFB Brood Bees AFB Brood Bees AFB Brood Bees AFB
Control 118 2 3 0 2 4 1 2 3 2 3 4 4 4 5 4
Control 107 2 3 0 1 2 1 0 0 6 0 0 6 0 0 6
Control 144 2 3 0 2 4 1 2 3 0 2 3 5 2 3 5
Control 71 2 4 0 2 3 0 3 4 0 3 4 0 5 5 1
Control 102 2 3 0 1 3 0 2 3 0 2 3 5 0 0 6
Tylosin 42 2 4 0 2 4 0 2 2 0 3 4 0 4 5 0
Tylosin 111 2 4 0 2 4 0 2 4 0 3 5 0 4 5 0
Tylosin 108 2 4 0 2 4 0 2 3 0 4 5 0 8 5 0
Tylosin 112 2 4 0 2 4 0 2 2 0 3 4 0 4 5 0
Tylosin 41 2 3 0 2 4 0 3 4 0 4 5 0 3 5 0Overall the results were consistent over 3 years of
field experiments, in relation to infection level
variable, both the Wilcoxon and the Fisher tests
showed similar results. The tylosin treated colonies
showed significant differences respect compared to the
AFB-inoculated controls ( p < 0.05). Likewise, the
analysis of the infection variable in all three
experiments together with the Fisher and Mantel
Haenszel Chi-square tests gave significant differences
for tylosin compared to those of the AFB-inoculated
controls (Fisher p < 0.05; Mantel Haenszel Chi-
square = 17,364, p < 0.05) (Fig. 2). The result of
the analysis of the brood variable in all three
experiments under the Fisher test showed significant
differences for tylosin compared to the AFB-
inoculated controls ( p < 0.05), which confirms the
high effectiveness of tylosin. The analysis for the adultFig. 2. Severity scores of larvae with AFB-clinical symptoms in
tylosin treated and control colonies at the last inspection date during
2000, 2001 and 2002 field experiments.bee variable in all three experiments under the Fisher
test showed no significant differences between tylosin
and the AFB-inoculated controls ( p > 0.05). The
reason for this could lay in the fact that during the
autumn–winter season workers show an increase in
lifespan associated with the decrease in the queen’s
egg laying capabilities. Thus, the disease had no
noticeable effects on adults throughout the experi-
ments.
Our results agree with publication data from other
researchers about the effectiveness of tylosin for
controlling clinical symptoms of AFB. Our previous
studies (Alippi et al., 1999) demonstrated the efficacy
of tylosin to control AFB by using a formulation of
1500 mg a.i. of tylosin tartrate applied in extender
patties or in paper pack in suppressing AFB clinical
signs after 1 year after treatment. Peng et al. (1996)
found that dosages of 100 and 200 mg of tylosin
protected the colonies for 3 and 4 weeks, respectively,
but an additional feeding of tylosin at 100, 200, 400
and 800 mg doses can eliminate the signs of infection
for an additional 3-week period. Peng et al. (1996) also
noticed that bees were reluctant to accept 800 mg
tylosin/7 g sugar dose, taking more than 4 weeks for
its consumption. In our study bees took less than 21
days to consume 750 mg tylosin tartrate supplied with
syrup, probably due to the addition of raspberry
essence to improve the taste. Elzen et al. (2002a,b)
working with colonies with different levels of
infection with oxytetracycline-resistant AFB from a
commercial apiary managed to control the infection in
15 and 45 days, respectively, by sprinkling 200 and
400 mg powdered tylosin tartrate. No re-infection was
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Table 3
Clinical symptoms of AFB and amount of healthy brood and adult bees per colony and inspection date during the second field experiment starting
in April 13, 2001
Treatment Colony
number
May 13 June 10 July 8 August 5
Brood Bees AFB Brood Bees AFB Brood Bees AFB Brood Bees AFB
Control 16 D 1 2 0 1 2 1 2 2 3 1 2 3
Control 10 D 1 3 0 2 3 0 2 3 1 2 3 1
Control 14 D 2 3 3 2 3 4 2 2 5 0 0 6
Control 17 D 2 3 0 2 3 2 2 3 3 2 4 3
Control 4 D 2 3 0 2 3 1 2 3 2 2 4 3
Tylosin 3 E 2 3 0 2 3 0 2 3 0 2 3 0
Tylosin 5 E 2 3 0 1 2 0 2 3 1 2 3 1
Tylosin 15 E 2 3 0 2 3 0 2 3 1 2 3 0
Tylosin 6 E 2 3 0 1 2 0 1 2 0 1 2 0
Tylosin 12 E 2 3 0 2 3 0 2 3 0 2 3 0observed 7 months after treatment at both doses, while
with doses of 100 mg colonies showed clinical signs of
the disease after 3 weeks. In another trial, Elzen et al.
(2002a,b) demonstrated that a total dose of 600 mg
tylosin over 3 weeks applied as a dust in a powered
sugar mixture effectively controls AFB during 3
months, the authors also tested a greasy patty method
of application with an equivalent weekly tylosin
dosage and found that the method was also effective.
However, in all colonies treated with patties bee
populations were significantly reduced due to the
invasion and proliferation of the small hive beetle
Aethina tumida that consume the food sources of a
colony, including a greasy patty.
Regarding the form of application and the doses of
tylosin used in our study, no significant differences
were found among our three experiments ( p < 0.005),Table 4
Clinical symptoms of AFB and amount of healthy brood and adult bees per c
May 22, 2002
Treatment Colony
number
June 22 July 21 Au
Brood Bees AFB Brood Bees AFB Br
Control 4 C 2 3 1 2 3 1 2
Control 11 C 3 2 0 2 3 0 2
Control 14 C 2 3 0 1 3 0 2
Control 3 C 2 3 2 2 3 3 1
Control 8 C 2 3 1 2 3 2 2
Control 9 C 2 4 1 2 3 0 2
Tylosin 41 A 2 3 0 2 3 0 2
Tylosin 30 A 2 3 0 1 3 0 1
Tylosin 2 A 2 3 0 1 3 0 2
Tylosin 5 A 2 3 0 1 3 0 1
Tylosin 7 A 2 4 0 2 3 0 1
Tylosin 17 A 2 3 0 2 3 0 2but taking into account that tylosin is converted into
desmycosin that could remain stable in honey over 9
months (Kochanski, 2004a,b) we suggest to use a
single dose of 750 mg and also in autumn treatment to
prevent persistent residues in honey. Applications in
syrup are not convenient because it is stored directly
by the bees, and any applications during the nectar
flow when honey is being stored should be avoided.
Nevertheless, the results obtained from Kochanski
(2004b) were from honeys prepared by adding tylosin
under laboratory conditions. Further studies are
needed to determine the fate of tylosin and desmy-
cosin residues in honey and royal jelly under field
conditions at the recommended doses for field trials,
and also the disposition profile of tylosin and
desmycosin among honeybees, larvae and pupae for
understanding its pharmacokinetics in bee colonies.olony and inspection date during the first field experiment starting in
gust 14 September 18 October 20
ood Bees AFB Brood Bees AFB Brood Bees AFB
2 1 1 2 5 0 0 6
3 0 2 3 0 3 5 1
3 0 2 3 0 3 4 1
2 5 0 0 6 0 0 6
3 1 2 3 3 2 2 4
3 0 2 3 0 4 4 1
3 0 2 2 0 2 3 0
2 0 1 2 0 2 3 1
2 0 1 2 0 2 2 0
3 0 2 3 0 2 3 0
3 0 2 2 0 2 3 0
3 0 2 3 0 3 3 0
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